Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
NCT ID: NCT01467700
Last Updated: 2016-05-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
490 participants
INTERVENTIONAL
2011-12-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder
NCT01467713
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
NCT01677182
A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder
NCT01685151
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
NCT03249376
A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder
NCT00037674
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be seen twice during the first week of treatment, weekly during the first 2 weeks of treatment and then every 2 weeks up to the end of the 8-week treatment period. Participants who complete the 8-week treatment period will have a follow-up visit approximately seven days after the last visit. A safety follow-up phone call will be made 30 days after completion of the 8-week treatment period.
Based on the recommendation of the Independent Data Monitoring Committee which determined that the study data had met pre-determined criteria for futility, Takeda has made a decision to terminate the study. No safety concerns were identified by the Independent Data Monitoring Committee
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ramelteon SL 0.1 mg
Ramelteon SL 0.1 mg, tablets, sublingual (SL) \[dissolved under the tongue\], once daily (QD), every night at bedtime for up to 8 weeks.
Ramelteon SL
Ramelteon SL tablets
Ramelteon SL 0.4 mg
Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
Ramelteon SL
Ramelteon SL tablets
Ramelteon SL 0.8 mg
Ramelteon SL 0.8 mg tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
Ramelteon SL
Ramelteon SL tablets
Placebo
Ramelteon SL placebo-matching, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
Placebo
Ramelteon placebo-matching tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ramelteon SL
Ramelteon SL tablets
Placebo
Ramelteon placebo-matching tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
3. The participant is a man or woman aged between 18 and 75 years, inclusive.
4. The participant suffers from Bipolar I Disorder, Most Recent Episode Depressed as the primary diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria (classification code 296.5x) and confirmed by the Structured Clinical Interview for DSM Disorders (SCID).
5. The reported duration of the current Major Depressive Episode (MDE) is at least four weeks and less than 6 months.
6. The participant has a Young Mania Rating Scale (YMRS) score of ≤10 both at the Screening and Baseline visits.
7. The participant has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥24 at the Screening and Baseline Visits.
8. The participant has a Clinical Global Impression Scale - Severity (CGI-S) score of ≥4 at the Screening and Baseline Visits.
9. Hamilton Rating Scale for Anxiety (HAM-A) score is ≤21 at Screening and Baseline visits.
10. The participant has a lithium and/or valproate levels within therapeutic range (0.6 - 1.2 mEq/L for lithium or 50-125 mcg/ml for valproate) at screening. If the patient does not have a lithium and/or valproate level within therapeutic range at screening, they must have a lithium and/or valproate levels within the therapeutic range between Day - 15 to Day -30 of screening.
11. A female participant of childbearing potential who is sexually active and agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose.
12. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent through the duration of the study and for 30 days after the last dose.
Exclusion Criteria
2. The participant has received ramelteon in a previous clinical study or has ever used ramelteon.
3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
4. The participant has one or more of the following:
* Any current psychiatric disorder other than Bipolar I Disorder, Most Recent Episode Depressed as defined in the DSM-IV-TR, as assessed by the SCID.
* Current or history of: schizophrenia, unipolar depression with psychotic features, bipolar depression with psychotic features, any other psychotic disorder (with the exception of psychosis associated with a manic episode), mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
* Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least one year from the day of screening. (Participant must also have negative urine drug screen prior to Baseline).
* Presence or history of a clinically significant neurological disorder (including epilepsy).
* Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
* Any Axis II disorder that might compromise the study.
* History of Rapid Cycling Bipolar Disorder: Patients who have more than 8 episodes of mood disorder per year.
5. The participant experienced the first episode of mood disorder after the age of 65 years.
6. The current depressive symptoms of the participant are considered by the investigator to have been resistant to 2 adequate treatment trials with any of the mood stabilizers (specifically started to treat the current depressive episode) and/or antidepressant medications of at least 6 weeks duration each.
7. The participant is on any other psychotropic medications except for lithium (serum levels 0.8 to mEq/L) or valproate (serum levels 50 to 125 mcg/ml) at the Screening visit.
8. The participant is on lithium and/or valproate for less than 30 days prior to screening.
9. If the participant is on antidepressant medications and/or antipsychotic medications (used as a mood stabilizer) and the patient is considered appropriate by the PI, these medications must be washed out for at least 2 weeks prior to the Screening visit.
10. The participant has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
11. The participant has started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days prior to screening or plans to initiate such therapy during the study.
12. The participant has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥ 5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
13. The participant has taken or is anticipated that the participant will take at least 1 of the disallowed concomitant medications.
14. The participant has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance as determined by Investigator.
15. The participant has a history or current diagnosis of Fibromyalgia, Chronic Fatigue Syndrome, Chronic Pain Syndrome or Sleep apnea.
16. The participant has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include those participants with basal cell or stage I squamous cell carcinoma of the skin.
17. The participant has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the participant has any of the following values at the Screening Visit:
* A serum creatinine value \>1.5 times the upper limits of normal (xULN).
* A serum total bilirubin value \>1.5 xULN.
* A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \>2 xULN.
18. The participant has glycosylated hemoglobin (HbA1C) ≥7% at baseline and no prior diagnosis of diabetes and/or treatment for diabetes. NOTE: Participants with known diabetes are not excluded.
19. The participant has a thyroid stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator. If TSH is outside the normal range, a free T4 will be obtained.
20. The participant has clinically significant abnormal vital signs as determined by the investigator.
21. The participant has an abnormal electrocardiogram (ECG) as determined by the central reader and confirmed as clinically significant by the investigator.
22. The participant has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
23. The participant, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director Clinical Science
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Dothan, Alabama, United States
Muscle Shoals, Alabama, United States
Phoenix, Arizona, United States
Fayetteville, Arkansas, United States
Little Rock, Arkansas, United States
Bellflower, California, United States
Costa Mesa, California, United States
Garden Grove, California, United States
Harbor City, California, United States
Huntington Park, California, United States
Irvine, California, United States
Lomita, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Murrieta, California, United States
National City, California, United States
Oceanside, California, United States
Orange, California, United States
Paramount, California, United States
Rancho Cucamonga, California, United States
Redondo Beach, California, United States
Riverside, California, United States
Sacramento, California, United States
San Diego, California, United States
San Jose, California, United States
San Ramon, California, United States
Sherman Oaks, California, United States
Torrance, California, United States
Wildomar, California, United States
Colorado Springs, Colorado, United States
Denver, Colorado, United States
Norwalk, Connecticut, United States
Washington D.C., District of Columbia, United States
Clearwater, Florida, United States
Coral Gables, Florida, United States
Coral Springs, Florida, United States
Edgewater, Florida, United States
Hialeah, Florida, United States
Jacksonville, Florida, United States
Leesburg, Florida, United States
Miami, Florida, United States
Miami Beach, Florida, United States
Miami Lakes, Florida, United States
Orange City, Florida, United States
Orlando, Florida, United States
Pembroke Pines, Florida, United States
Plantation, Florida, United States
Port Charlotte, Florida, United States
Saint Cloud, Florida, United States
Tampa, Florida, United States
Vero Beach, Florida, United States
Atlanta, Georgia, United States
Dunwoody, Georgia, United States
East Point, Georgia, United States
Smyrna, Georgia, United States
Suwanee, Georgia, United States
Honolulu, Hawaii, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Gurnee, Illinois, United States
Hoffman Estates, Illinois, United States
Libertyville, Illinois, United States
Skokie, Illinois, United States
Brownsburg, Indiana, United States
Manhattan, Kansas, United States
Topeka, Kansas, United States
Wichita, Kansas, United States
Elizabethtown, Kentucky, United States
Lexington, Kentucky, United States
Paducah, Kentucky, United States
Mandeville, Louisiana, United States
Metairie, Louisiana, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Fall River, Massachusetts, United States
Bloomfield Hills, Michigan, United States
Detroit, Michigan, United States
Kalamazoo, Michigan, United States
Flowood, Mississippi, United States
Hazelwood, Missouri, United States
Saint Charles, Missouri, United States
St Louis, Missouri, United States
Washington, Missouri, United States
Lincoln, Nebraska, United States
Las Vegas, Nevada, United States
Cherry Hill, New Jersey, United States
Albuquerque, New Mexico, United States
Brooklyn, New York, United States
Cedarhurst, New York, United States
Fresh Meadows, New York, United States
New York, New York, United States
Rochester, New York, United States
Staten Island, New York, United States
Charlotte, North Carolina, United States
Columbiana, North Carolina, United States
Durham, North Carolina, United States
Greensboro, North Carolina, United States
Raleigh, North Carolina, United States
Salisbury, North Carolina, United States
Wilmington, North Carolina, United States
Fargo, North Dakota, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
Allentown, Pennsylvania, United States
Duncansville, Pennsylvania, United States
Harleysville, Pennsylvania, United States
McMurray, Pennsylvania, United States
Media, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Lincoln, Rhode Island, United States
Columbia, South Carolina, United States
Greer, South Carolina, United States
Old Point Station, South Carolina, United States
Clarksville, Tennessee, United States
Knoxville, Tennessee, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Bellaire, Texas, United States
Corpus Christi, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Irving, Texas, United States
Nassau Bay, Texas, United States
Plano, Texas, United States
San Antonio, Texas, United States
Bountiful, Utah, United States
Newport News, Virginia, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
Kirkland, Washington, United States
Richland, Washington, United States
Seattle, Washington, United States
Clarksburg, West Virginia, United States
Milwaukee, Wisconsin, United States
Buenos Aires, , Argentina
Córdoba, , Argentina
Mendoza, , Argentina
Santa Fe, , Argentina
Antofagasta, , Chile
Arauco, , Chile
Elqui, , Chile
Santiago, , Chile
Bello, Antioquia, Colombia
Antioquia, , Colombia
Barranquilla, , Colombia
Bogotá, , Colombia
Mexicali, Estado de Baja California, Mexico
León, Guanajuato, Mexico
Mexico City, Mexico City, Mexico
Monterrey, Nuevo León, Mexico
San Lucas, Tepetlacalco, Mexico
Mérida, Yucatán, Mexico
México, , Mexico
San Luis Potosí City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1122-7380
Identifier Type: REGISTRY
Identifier Source: secondary_id
TAK-375SL_201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.